| Literature DB >> 35550257 |
Julien Vibert1, Olivier Saulnier2, Céline Collin2, Floriane Petit2, Kyra J E Borgman3, Jérômine Vigneau2, Maud Gautier2, Sakina Zaidi2, Gaëlle Pierron4, Sarah Watson5, Nadège Gruel6, Clémence Hénon7, Sophie Postel-Vinay8, Marc Deloger9, Virginie Raynal10, Sylvain Baulande10, Karine Laud-Duval2, Véronique Hill2, Sandrine Grossetête2, Florent Dingli11, Damarys Loew11, Jacob Torrejon12, Olivier Ayrault12, Martin F Orth13, Thomas G P Grünewald14, Didier Surdez2, Antoine Coulon3, Joshua J Waterfall15, Olivier Delattre16.
Abstract
Many cancers are characterized by gene fusions encoding oncogenic chimeric transcription factors (TFs) such as EWS::FLI1 in Ewing sarcoma (EwS). Here, we find that EWS::FLI1 induces the robust expression of a specific set of novel spliced and polyadenylated transcripts within otherwise transcriptionally silent regions of the genome. These neogenes (NGs) are virtually undetectable in large collections of normal tissues or non-EwS tumors and can be silenced by CRISPR interference at regulatory EWS::FLI1-bound microsatellites. Ribosome profiling and proteomics further show that some NGs are translated into highly EwS-specific peptides. More generally, we show that hundreds of NGs can be detected in diverse cancers characterized by chimeric TFs. Altogether, this study identifies the transcription, processing, and translation of novel, specific, highly expressed multi-exonic transcripts from otherwise silent regions of the genome as a new activity of aberrant TFs in cancer.Entities:
Keywords: chimeric transcription factors; long non-coding RNAs; sarcomas; tumor-specific peptides; tumor-specific transcripts
Mesh:
Substances:
Year: 2022 PMID: 35550257 DOI: 10.1016/j.molcel.2022.04.019
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 19.328